These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 10986055)

  • 1. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.
    Thor AD; Liu S; Edgerton S; Moore D; Kasowitz KM; Benz CC; Stern DF; DiGiovanna MP
    J Clin Oncol; 2000 Sep; 18(18):3230-9. PubMed ID: 10986055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.
    Eppenberger-Castori S; Kueng W; Benz C; Caduff R; Varga Z; Bannwart F; Fink D; Dieterich H; Hohl M; Müller H; Paris K; Schoumacher F; Eppenberger U
    J Clin Oncol; 2001 Feb; 19(3):645-56. PubMed ID: 11157014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
    Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
    Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.
    Murphy NC; Biankin AV; Millar EK; McNeil CM; O'Toole SA; Segara D; Crea P; Olayioye MA; Lee CS; Fox SB; Morey AL; Christie M; Musgrove EA; Daly RJ; Lindeman GJ; Henshall SM; Visvader JE; Sutherland RL
    Int J Cancer; 2010 Mar; 126(6):1445-53. PubMed ID: 19676041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers.
    Thor AD; Edgerton SM; Liu S; Moore DH; Kwiatkowski DJ
    Clin Cancer Res; 2001 Aug; 7(8):2415-24. PubMed ID: 11489821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.
    Tokatli F; Altaner S; Uzal C; Ture M; Kocak Z; Uygun K; Bilgi S
    Exp Oncol; 2005 Jun; 27(2):145-9. PubMed ID: 15995634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
    Esteva FJ; Sahin AA; Smith TL; Yang Y; Pusztai L; Nahta R; Buchholz TA; Buzdar AU; Hortobagyi GN; Bacus SS
    Cancer; 2004 Feb; 100(3):499-506. PubMed ID: 14745865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Different influence of Her-2 expression on the prognosis in node-positive and node-negative breast cancer].
    Wang Y; Yao L; Liu YQ; Xu Y; Ou YT; Li JF; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):511-4. PubMed ID: 21029694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.
    Konecny GE; Meng YG; Untch M; Wang HJ; Bauerfeind I; Epstein M; Stieber P; Vernes JM; Gutierrez J; Hong K; Beryt M; Hepp H; Slamon DJ; Pegram MD
    Clin Cancer Res; 2004 Mar; 10(5):1706-16. PubMed ID: 15014023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
    Hudelist G; Köstler WJ; Czerwenka K; Kubista E; Attems J; Müller R; Gschwantler-Kaulich D; Manavi M; Huber I; Hoschützky H; Zielinski CC; Singer CF
    Int J Cancer; 2006 Mar; 118(5):1126-34. PubMed ID: 16161043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
    DiGiovanna MP; Stern DF; Edgerton SM; Whalen SG; Moore D; Thor AD
    J Clin Oncol; 2005 Feb; 23(6):1152-60. PubMed ID: 15718311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.
    Hudelist G; Köstler WJ; Attems J; Czerwenka K; Müller R; Manavi M; Steger GG; Kubista E; Zielinski CC; Singer CF
    Br J Cancer; 2003 Sep; 89(6):983-91. PubMed ID: 12966413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.
    Mehta RR; McDermott JH; Hieken TJ; Marler KC; Patel MK; Wild LD; Das Gupta TK
    J Clin Oncol; 1998 Jul; 16(7):2409-16. PubMed ID: 9667258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.
    Sjögren S; Inganäs M; Lindgren A; Holmberg L; Bergh J
    J Clin Oncol; 1998 Feb; 16(2):462-9. PubMed ID: 9469329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
    Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
    Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship of c-FLIP(L) protein expression with molecular subtyping and clinical prognosis in invasive breast cancer].
    Zang F; Wei X; Sun B
    Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):442-6. PubMed ID: 25327791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.